IDEXX Laboratories (NASDAQ:IDXX) Announces Quarterly Earnings Results

IDEXX Laboratories (NASDAQ:IDXX) released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06, Zacks reports. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period last year, the business posted $2.91 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories updated its FY 2026 guidance to 14.450-14.900 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• Raised full?year guidance — revenue now $4.675B–$4.76B and EPS $14.45–$14.90, with organic revenue growth guidance of 7.7%–9.7% and CAG Diagnostics recurring growth of 8.7%–10.7%, reflecting a roughly $42M midpoint improvement from Q1 execution.
• Strong Q1 operating performance — revenue +14% reported (+11% organic), CAG Diagnostics recurring revenue +11%, 1,100 InViewDX placements and 28% organic instrument revenue growth, VetLab consumables +15%, and a 100 bp comparable operating margin gain driving 15% comparable EPS growth.
• Demand headwinds in visits — U.S. same?store clinical visits declined ~1% in Q1 (wellness visits -3%) and the company is guiding to ~-1.5% U.S. clinical visits for the year, which could constrain future volume growth if trends persist.
• One?time and FX effects — Q1 included a $5M loss on an equity investment (~$0.05 EPS headwind) and a prior litigation expense (~30 bp margin impact), while FX added about $0.14 to EPS; balance sheet remains strong (0.5x net leverage) after $361M of share repurchases.

IDEXX Laboratories Trading Down 0.8%

Shares of NASDAQ IDXX traded down $4.18 during trading on Friday, hitting $528.68. 378,059 shares of the company were exchanged, compared to its average volume of 536,472. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories has a 12-month low of $496.61 and a 12-month high of $769.98. The company has a fifty day moving average price of $574.48 and a 200-day moving average price of $646.38. The firm has a market capitalization of $41.70 billion, a PE ratio of 38.93, a P/E/G ratio of 3.08 and a beta of 1.58.

Insider Activity

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the transaction, the executive vice president directly owned 18,141 shares of the company’s stock, valued at $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the transaction, the director owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 34,612 shares of company stock valued at $22,525,070 in the last ninety days. 0.79% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtus Advisers LLC purchased a new position in IDEXX Laboratories in the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd purchased a new position in IDEXX Laboratories in the 3rd quarter valued at $36,000. WealthCollab LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at $30,000. Johnson Financial Group Inc. raised its position in IDEXX Laboratories by 1,475.0% during the 3rd quarter. Johnson Financial Group Inc. now owns 63 shares of the company’s stock worth $40,000 after buying an additional 59 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in IDEXX Laboratories during the 4th quarter worth $54,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. UBS Group decreased their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. BTIG Research reduced their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.